These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 25243412)

  • 1. Investigational selectin-targeted therapy of sickle cell disease.
    Okpala I
    Expert Opin Investig Drugs; 2015 Feb; 24(2):229-38. PubMed ID: 25243412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cellular adhesion and the endothelium: E-selectin, L-selectin, and pan-selectin inhibitors.
    Telen MJ
    Hematol Oncol Clin North Am; 2014 Apr; 28(2):341-54. PubMed ID: 24589270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cellular adhesion and the endothelium: P-selectin.
    Kutlar A; Embury SH
    Hematol Oncol Clin North Am; 2014 Apr; 28(2):323-39. PubMed ID: 24589269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A potent oral P-selectin blocking agent improves microcirculatory blood flow and a marker of endothelial cell injury in patients with sickle cell disease.
    Kutlar A; Ataga KI; McMahon L; Howard J; Galacteros F; Hagar W; Vichinsky E; Cheung AT; Matsui N; Embury SH
    Am J Hematol; 2012 May; 87(5):536-9. PubMed ID: 22488107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of Sickle Red Blood Cell Adhesion and its Associated Changes in Biomarkers by Sulfated Nonanticoagulant Heparin Derivative.
    Alshaiban A; Muralidharan-Chari V; Nepo A; Mousa SA
    Clin Appl Thromb Hemost; 2016 Apr; 22(3):230-8. PubMed ID: 25601897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can selectin and iNKT cell therapies meet the needs of people with sickle cell disease?
    Field JJ
    Hematology Am Soc Hematol Educ Program; 2015; 2015():426-32. PubMed ID: 26637753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sevuparin binds to multiple adhesive ligands and reduces sickle red blood cell-induced vaso-occlusion.
    Telen MJ; Batchvarova M; Shan S; Bovee-Geurts PH; Zennadi R; Leitgeb A; Brock R; Lindgren M
    Br J Haematol; 2016 Dec; 175(5):935-948. PubMed ID: 27549988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The fucosylation inhibitor, 2-fluorofucose, inhibits vaso-occlusion, leukocyte-endothelium interactions and NF-ĸB activation in transgenic sickle mice.
    Belcher JD; Chen C; Nguyen J; Abdulla F; Nguyen P; Nguyen M; Okeley NM; Benjamin DR; Senter PD; Vercellotti GM
    PLoS One; 2015; 10(2):e0117772. PubMed ID: 25706118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging pharmacotherapeutic approaches for the management of sickle cell disease.
    Torres L; Conran N
    Expert Opin Pharmacother; 2019 Feb; 20(2):173-186. PubMed ID: 30499731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GMI-1070, a novel pan-selectin antagonist, reverses acute vascular occlusions in sickle cell mice.
    Chang J; Patton JT; Sarkar A; Ernst B; Magnani JL; Frenette PS
    Blood; 2010 Sep; 116(10):1779-86. PubMed ID: 20508165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting Neutrophil Adhesive Events to Address Vaso-Occlusive Crisis in Sickle Cell Patients.
    Morikis VA; Hernandez AA; Magnani JL; Sperandio M; Simon SI
    Front Immunol; 2021; 12():663886. PubMed ID: 33995392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RNA aptamer therapy for vaso-occlusion in sickle cell disease.
    Burnette AD; Nimjee SM; Batchvarova M; Zennadi R; Telen MJ; Nishimura J; Sullenger BA
    Nucleic Acid Ther; 2011 Aug; 21(4):275-83. PubMed ID: 21793788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Markers of endothelial dysfunction and leucocyte activation in Saudi and non-Saudi haplotypes of sickle cell disease.
    Al Najjar S; Adam S; Ahmed N; Qari M
    Ann Hematol; 2017 Jan; 96(1):141-146. PubMed ID: 27686084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selectin inhibitors: a patent review.
    Bedard PW; Kaila N
    Expert Opin Ther Pat; 2010 Jun; 20(6):781-93. PubMed ID: 20408735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 1 study of the E-selectin inhibitor GMI 1070 in patients with sickle cell anemia.
    Wun T; Styles L; DeCastro L; Telen MJ; Kuypers F; Cheung A; Kramer W; Flanner H; Rhee S; Magnani JL; Thackray H
    PLoS One; 2014; 9(7):e101301. PubMed ID: 24988449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heparin inhibits the flow adhesion of sickle red blood cells to P-selectin.
    Matsui NM; Varki A; Embury SH
    Blood; 2002 Nov; 100(10):3790-6. PubMed ID: 12393591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of cell adhesion by anti-P-selectin aptamer: a new potential therapeutic agent for sickle cell disease.
    Gutsaeva DR; Parkerson JB; Yerigenahally SD; Kurz JC; Schaub RG; Ikuta T; Head CA
    Blood; 2011 Jan; 117(2):727-35. PubMed ID: 20926770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Leukocyte adhesion to P-selectin and the inhibitory role of Crizanlizumab in sickle cell disease: A standardized microfluidic assessment.
    Man Y; Goreke U; Kucukal E; Hill A; An R; Liu S; Bode A; Solis-Fuentes A; Nayak LV; Little JA; Gurkan UA
    Blood Cells Mol Dis; 2020 Jul; 83():102424. PubMed ID: 32208292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospects for early investigational therapies for sickle cell disease.
    Conran N
    Expert Opin Investig Drugs; 2015 May; 24(5):595-602. PubMed ID: 25682977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leukotriene pathway in sickle cell disease: a potential target for directed therapy.
    Knight-Perry J; DeBaun MR; Strunk RC; Field JJ
    Expert Rev Hematol; 2009 Feb; 2(1):57-68. PubMed ID: 21082995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.